The finding was principally derived from one RCT (PARADIGM-HF)5 that showed about 16% reduction of all-cause mortality in favour of sacubitril/valsartan (LCZ696 previously) compared with enalapril (an ACE-i). Here, ACE is linked to hydrops fetalis.